AR080197A1 - Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk 4/6 - Google Patents

Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk 4/6

Info

Publication number
AR080197A1
AR080197A1 ARP110100477A ARP110100477A AR080197A1 AR 080197 A1 AR080197 A1 AR 080197A1 AR P110100477 A ARP110100477 A AR P110100477A AR P110100477 A ARP110100477 A AR P110100477A AR 080197 A1 AR080197 A1 AR 080197A1
Authority
AR
Argentina
Prior art keywords
compound
inhibitors
cdk4
cancer
pirrolopirimidine
Prior art date
Application number
ARP110100477A
Other languages
English (en)
Inventor
Christopher Thomas Brain
Lawrence Blas Perez
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR080197A1 publication Critical patent/AR080197A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos son inhibidores de la CDK4/6 y podrían ser utiles en el tratamiento de enfermedades y trastornos mediados por la CDK4/6, tales como el cáncer, incluyendo linfoma de células de manto, liposarcoma, cáncer pulmonar de células no pequenas, melanoma, cáncer esofágico de células escamosas y cáncer de mama. Además está dirigido a composiciones farmacéuticas que comprenden un compuesto, y a métodos de inhibir la actividad de la CDK4/6 y al tratamiento de trastornos asociados con la misma utilizando un compuesto o una composicion farmacéutica que comprende un compuesto. Reivindicacion 1: Un compuesto segun la formula (1) en donde: R1 es hidrogeno, metilo, CH2D, CHD2, o CD3; y R2 es CH2D, CHD2, o CD3 o una sal de los mismos.
ARP110100477A 2010-02-19 2011-02-17 Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk 4/6 AR080197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30624810P 2010-02-19 2010-02-19

Publications (1)

Publication Number Publication Date
AR080197A1 true AR080197A1 (es) 2012-03-21

Family

ID=44168434

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100477A AR080197A1 (es) 2010-02-19 2011-02-17 Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk 4/6

Country Status (15)

Country Link
US (1) US20130203765A1 (es)
EP (1) EP2536727B1 (es)
JP (1) JP2013519708A (es)
KR (1) KR20130008557A (es)
CN (1) CN103003280A (es)
AR (1) AR080197A1 (es)
AU (1) AU2011217199B2 (es)
BR (1) BR112012020704A2 (es)
CA (1) CA2790641A1 (es)
EA (1) EA201201159A1 (es)
GT (1) GT201200242A (es)
MX (1) MX2012009606A (es)
TW (1) TW201136934A (es)
UY (1) UY33226A (es)
WO (1) WO2011101417A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20135785B (en) 2008-08-22 2013-03-11 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
EA201892726A1 (ru) * 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
LT2968290T (lt) 2013-03-15 2019-12-10 G1 Therapeutics Inc Laikina normalių ląstelių apsauga chemoterapijos metu
JP6435315B2 (ja) * 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
EP3033086B1 (en) 2013-08-14 2021-09-22 Novartis AG Combination therapy for the treatment of cancer
TWI558399B (zh) * 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
KR102601320B1 (ko) * 2015-05-29 2023-11-10 데이진 화-마 가부시키가이샤 피리도[3,4-d]피리미딘 유도체 및 그 약학적으로 허용되는 염
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
CN108290899B (zh) * 2016-06-06 2020-09-18 深圳市塔吉瑞生物医药有限公司 一种取代的吡咯并嘧啶化合物及其应用
KR102466192B1 (ko) 2016-08-23 2022-11-14 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포성 암종의 치료를 위한 조합 요법
CN106478641B (zh) * 2016-10-09 2018-07-24 杭州科巢生物科技有限公司 瑞博西尼中间体的合成方法
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018170447A1 (en) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
AU2018354972B2 (en) * 2017-10-27 2021-07-08 Fresenius Kabi Oncology Ltd. An improved process for the preparation of ribociclib and its salts
AU2019205821B2 (en) 2018-01-08 2024-07-18 G1 Therapeutics, Inc. G1T38 superior dosage regimes
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
JP7352981B2 (ja) * 2018-10-10 2023-09-29 深▲チェン▼市塔吉瑞生物医薬有限公司 ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
CN111100128B (zh) * 2018-10-26 2022-09-06 广安凯特制药有限公司 一种瑞博西尼中间产品的合成方法及其中间体化合物
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
JP2024520461A (ja) * 2021-05-24 2024-05-24 大鵬薬品工業株式会社 Ｅｇｆｒ及び／又はｈｅｒ２に異常を有するがんを有する対象の治療方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
ATE314388T1 (de) * 1997-10-08 2006-01-15 Isotechnika Inc Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
MX2008011868A (es) * 2006-03-16 2008-12-15 Vertex Pharma Inhibidores deuterados de la proteasa de la hepatitis c.
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
CN101981036B (zh) * 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
GEP20135785B (en) * 2008-08-22 2013-03-11 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors

Also Published As

Publication number Publication date
AU2011217199A1 (en) 2012-08-30
US20130203765A1 (en) 2013-08-08
CN103003280A (zh) 2013-03-27
GT201200242A (es) 2015-06-02
EA201201159A1 (ru) 2013-04-30
JP2013519708A (ja) 2013-05-30
WO2011101417A1 (en) 2011-08-25
BR112012020704A2 (pt) 2016-07-26
AU2011217199B2 (en) 2014-05-15
TW201136934A (en) 2011-11-01
CA2790641A1 (en) 2011-08-25
KR20130008557A (ko) 2013-01-22
UY33226A (es) 2011-09-30
EP2536727B1 (en) 2014-07-02
MX2012009606A (es) 2012-09-12
EP2536727A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
AR080197A1 (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk 4/6
ECSP12012111A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
DOP2014000058A (es) 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
UY32251A (es) Compuestos quimicos
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
WO2012061557A3 (en) Chemical compounds
MX336381B (es) Boronatos como inhibidores de arginasa.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
UA109199C2 (uk) Дигідропіридинові сполуки, корисні для лікування від залежності, викликаної агентами, що стимулюють вироблення дофаміну
CR20110059A (es) Compuestos organicos
NZ706739A (en) Substituted benzene compounds
EA201201648A1 (ru) Стимуляторы sgc
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
MX2012013274A (es) Novedosos derivados de la pirimidina.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
NZ700283A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
EA201391334A1 (ru) Ингибиторы hsp90
MX360330B (es) Regimen de administracion para nitrocatecoles.
NZ718576A (en) Substituted pyrimidine compounds and their use as syk inhibitors
BR112014013411A2 (pt) derivados de ureia cíclica como antagonistas de receptores androgênicos
CU20120120A7 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
BR112014003100A2 (pt) emprego de mad2l2 como um marcador de estratificação no tratamento de tumores de mama com novos inibidores pan-cdk
WO2014030142A3 (en) Nitroimidazole compounds and their use in cancer therapy

Legal Events

Date Code Title Description
FB Suspension of granting procedure